1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > Tumor Markers: Unlocking the Mistery of the Genetic Basis of Cancer--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

Highlights

- Identifies and evaluates major business opportunities emerging in the tumor marker market during the next ten years
- Examines trends in the U.S., Europe and Japan
- Reviews current and emerging tumor markers
- Analyzes applications of emerging diagnostic technologies
- Forecasts sales of major tumor markers by country and market segment
- Profiles leading market players and potential entrants
- Suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

- France
- Germany
- Italy
- Japan
- Spain
- UK
- USA

Market Segmentation Analysis

- Sales and market shares of major suppliers, by individual tumor marker
and country.

- Ten-year test volume and sales forecasts for major
tumor markers by country and market segment,
including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers
by country.

- Cancer statistics, etiology and recent developments in the U.S., Japan and five major European countries.

Current and Emerging Products

- Review of over 200 current and emerging tumor markers,
including:

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- Analysis of major immunoassay analyzers used for
tumor marker testing, including their operating characteristics,
features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA
probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their
potential applications for tumor marker testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of over 500 companies, universities and
research centers developing new tumor markers and detection technologies.

Competitive Assessments

- Extensive strategic assessments of major suppliers and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

Worldwide Market Overview

- Estimated universe of laboratories performing tumor marker testing
by country.

- Ten-year test volume and sales projections by country.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next ten years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Methodology

This report is based on interviews with clinical pathologists, laboratory directors, executives from leading diagnostic companies and start-up firms developing innovative products, university scientists, as well as experts from industry associations, venture capital firms and the investment banking community in the U.S., five major European countries and Japan.

The market projections are also based on questionnaire responses received from hospitals, commercial/private laboratories, physician offices/group practices, cancer clinics and ambulatory care centers in seven countries.

In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer
product literature, patents, trade association surveys, government
studies, marketing and technical meeting presentations, industry analyst reports, and VPG's proprietary data files was conducted.

Contains 1,200 pages and 450 tables

Table Of Contents

Tumor Markers: Unlocking the Mistery of the Genetic Basis of Cancer--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Bladder
2. Breast
3. Cervical
4. Colon and Rectum
5. Endometrial
6. Esophagus
7. Head and Neck
8. Leukemia
9. Lung
10. Lymphoma
11. Oral
12. Ovarian
13. Prostate
14. Renal Cell Carcinoma
15. Skin
16. Stomach
17. Uterine
B. Major Current And Emerging Tumor Marker
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. Lymphocytes CD4/CD8
17. NSE
18. Occult Blood
19. PAP Smear/HPV
20. Prostatic Acid Phosphatase (PAP)
21. Prostate-Specific Antigen (PSA)
22. Squamous Cell Carcinoma Antigen (SCC)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- APC
- BTA 26
- BCL-2
- BCR-ABL
- B-raf
- BRCA
- CD44
- CDK
- C-abl
- C-fos
- C-myb
- C-myc
- CYCD1
- CYP-17
- DPC
- E-myc
- Erb-B
- HER-2/neu
- HPC1
- HSTF
- L-myc
- MET
- MSH
- NEU
- N-myc
- N-telopeptide
- PCA3
- PIK3CA
- PTI-1
- P10
- P40
- P51
? P53
? Ras
? Reg
? RET
? sFas
? Sis
- Src
28. Polypeptide Growth Factors
? Basic Fibroblast Growth Factor
? Beta-TGF
- Cachectin (TNT)
? Calmodulin
? ECFR
? Nerve Growth Factor (NGF)
? Epidermal Growth Factor (EGF)
? Ornithine Decarboxylase
? Transferrin
? Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
? Alpha-Interferon
? B Cell Growth Factors
? B Cell Growth Factor (BCGF)
? Gamma-Interferon
? Interleukin-1 (IL-1)
? Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
? N-Acetylglucosamine
? Actin
? Alpha-Actin
? Angiogenin
? Angiostatin
? Antineuronal Antibodies
- 7B2
? B72.3
- B-Protein
? Bax
- BCD-F9
? BLCA-4
- Blood Group Antigens A,B,H
? BTA
- CA 50
? CA 72-4/TAG-72
- CA 195
? CA-242
- CA-549
? Cadherin
- CAM 26
? CAR-3
- CD105
? Cathepsin-D
- Chromogranin A and B
? Cluster 1 Antigen
- Cluster-5/5A Antigen
? COX Antigen
- CTA
? CU18
- Cyclin
? DR-70
- DU-PAN-2
? Endometrial Bleeding Associated Factor
- Endostatin
? Epithelial Membrane Antigen
- FDP
? Feulgen Hydrolysis
- Fibronectin
? FSH
- (1->3)-L-fucosyltransferase
? Gastrin-Releasing Peptide (GRP)
- GDCFP-15
? Glucagon
- Glycoamines
? H23
- HAAH
? hk3
- HPA
? HSP27
- Human Carcinoma Antigen
? ICAM
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
? KA 93
- Kallikrein
- Kinases
? KP16D3
- LAI
? Leukocyte Common Antigen
- Lewis Antigens
? Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
? MABDF3
- MAG
? ME1
- Minactivin
? MN/CA9
- MSA
? Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
? Myosin
- NEA-130
? NMP22
- Nucleolar
- OA-519
? Opiod Peptides
- P-glycoprotein
? Pancreatic Oncofetal Antigen (POA)
- Parathyrcoid Hormone
? Placental Lactogen
- PR92
? Proliferative Index, Ki-67
- Px
? RB Inactivation/Deletion

- Ret
? S-100 Protein
- SCCL 175
? Selectin
- Serotonin
? Sialic Acid
- Sialyl SSEA-1/SLX
? SN10
- Somatostatin
? TA-90
- TABA
? Tachykinin
- TAG 12
? TPS
- Troponin
? Tubulin
- VCAM
? VEGF
- Villen
- White Blood Cell Markers
C. Instrumentation Review And
Market Needs
1. Abbott AxSYM
2. Abbott IMx
3. Anagen AN2000/AuraFlex
4. Beckman Coulter Access
5. BioChem Pharma SR1
6. bioMerieux Vidas Series
7. Biotrol Systems 7000
8. JandJ Diagnostics/Amersham Amerlite
9. JandJ Diagnostics Vitros ECI
10. Olympus PK Series
11. Roche Cobas Core
12. Roche Elecsys
13. Roche ES 22
14. Roche ES 33
15. Roche ES 300/300 AL
16. Siemens ACS: 180
17. Siemens ACS: Centaur
18. Siemens ELISA Processor II/III
19. Siemens Immuno 1
20. Siemens/Opus/Plus/Magnum
21. Siemens Stratus
22. Tosoh AIA Series
23. Wallac/Pharmacia Delfia
D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
4. Biochips/Microarrays
5. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas
Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
6. Microcomputers and Automation
7. Artificial Intelligence
8. Flow Cytometry
9. Biosensors
E. Competing/Complementing Technologies
1. CT
2. MRI
3. NMR
4. PET
5.Photonics Spectroscopy
F. Business Environment
1. Worldwide Market Structure
2. Worldwide Market Size and Growth
G. Personal Testing
France
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Germany
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Italy
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Japan
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Spain
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
U.S.A.
A. Executive Summary
B. Business Environment
1. Health Care Expenditures
2. Cost Consciousness
3. Reimbursement
4. Industry Consolidation
5. Managed Care
a. HMO
b. PPO
6. Hospitals
7. Admissions
8. Length of Stay
9. Industry Diversification
10. Physician Demographics
11. Population Aging
a. Chronic Illness
b. Disease Incidence
c. Susceptibility to Iatrogenesis
d. Multiple Illness Cases
12. Laboratory Regulations
13. FDA Reform
C. Market Structure
1. Centralized Testing
a. Hospitals
b. Commercial/Private Laboratories
2. POT/Decentralized Testing
a. Physician Offices/Group Practices
b. Cancer Clinics
c. Other Decentralized Testing Locations
D. Market Size, Growth and Major Suppliers Sales,
Instrument Placements and Market Shares
Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
- Abbott
- AdnaGen
- Ambrilia Biopharma
- AMDL
- Beckman Coulter
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CanAG Diagnostics
- CeMines
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- JandJ Diagnostics
- Kreatech
- Kyowa Medex
- Mackay Life Sciences
- Matritech
- Myriad Genetics
- OncoLab
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac
- Zila

Appendixes
Appendix I: Major Companies Developing or
Marketing Tumor Marker Reagents
and Instruments
Appendix II: Major Universities and Research
Centers Developing Tumor Marker
Detection
Technologies and Applications
Appendix III: Assumed Currency Exchange Rates

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2016 Competing in the Global Cancer Diagnostics Market

2016 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.